Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, and thus far, only efficacious symptomatic treatments have been developed, with PD remaining a progressive disease without a cure. In this week’s podcast Milton Werner, PhD, Inhibikase Therapeutics, Inc., Atlanta, GA; Daniel Otzen, PhD, Aarhus University,  Aarhus, Denmark; Charbel Moussa, MBBS, PhD,  Georgetown University Medical Center, Washington, D.C.; and Serge Przedborski, MD, PhD, Columbia University Irving Medical Center, New York, NY, discuss novel treatment approaches under investigation for PD.